Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials Authors: Zhonghua Tian, Yalin Yang, Mingchun Huang, Zhie Fang, Jixiong Mei, Yunyi Li, Ling Tang, Yanyan Li, Yuxia Li Published: 2025 ABSTRACT AbstractBackgroundIgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Dysregulation of cytokines B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) signaling pathway is associated with multiple core pathogenesis of IgAN patients and the elevation levels of serum BAFF and APRIL are positively correlated with the severity of the disease in IgAN patients. This study aimed to comprehensively evaluate the efficacy and safety of BAFF/APRIL dual antagonists in IgAN patients.MethodsLiterature search was performed using PubMed, Embase, Web of Science, Scopus and Cochrane Library from inception to 28 February 2025. All randomized controlled trials (RCTs) were identified. Data analysis was conducted using RevMan 5.4.ResultsThree Phase Ⅱ double-blind RCTs involving 263 primary IgAN patients were included. Compared with the control treatment, BAFF/APRIL dual antagonists achieved a greater percentage decrease from baseline in urine protein-to-creatinine ratio (UPCR) [mean difference (MD) -36.67, 95% confidence interval (CI) -40.31 to -33.03] and circulating galactose-deficient IgA1 (Gd-IgA1) (MD -45.55, 95% CI -61.33 to -29.78), while led to a greater increase from baseline in estimated glomerular filtration rate (eGFR) (MD 9.65, 95% CI 7.73 to 11.57). However, BAFF/APRIL dual antagonists were associated with a higher risk of injection site reactions [odds ratio (OR) 30.94, 95% CI 6.43 to 148.75] and greater percentage decrease from baseline in serum IgG (MD -22.65, 95% CI -33.83 to -11.48), IgA (MD -41.41, 95% CI -55.35 to -27.48) and IgM (MD -63.39, 95% CI -77.29 to -49.50).ConclusionBased on the currently limited evidence, we cautiously conclude that BAFF/APRIL dual antagonists may reduce the levels of 24-hour UPCR and circulating Gd-IgA1 in patients with IgAN, while concomitantly delay the decline of eGFR. However, it should be noted that BAFF/APRIL may cause injection site reactions. More importantly, BAFF/APRIL dual antagonists may reduce the levels of serum IgG, IgA and IgM, potentially weakening the immune function of patients.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12882-025-04689-w.Keywords: IgA nephropathy, BAFF/APRIL dual antagonists, Atacicept, Telitacicept, Meta-analysis Introduction Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease in the world [1–3]. Without effective treatment, a large number of IgAN patients will progress to end-stage renal disease (ESRD) within 20 years [4, 5]. Persistent proteinuria, uncontrollable hypertension and progressive kidney function loss are the strongest risk factors for the progression of IgAN patients, and each of which is an independent risk factor [6–8]. According to the KDIGO 2025 Clinical Practice Guideline, non-immunosuppressive therapy is the foundational treatment for all IgAN patients, including lifestyle modification, blood pressure (BP) management and maximum tolerated dose of renin-angiotensin system inhibitors [8]. For those patients at risk of progressive renal function loss, sodium-glucose cotransporter 2 (SGLT2) inhibitors and sparsentan are recommended. Systemic corticosteroids have been the cornerstone of immunosuppressive therapy in IgAN patients at risk of progressive renal function loss for decades. However, their use remains limited due to multiple adverse effects and frequent relapses requiring repeated courses. More critically, systematic corticosteroids have no pathogenetic effect on the disease and only transiently reduce intraglomerular inflammation. Mycophenolate mofetil, an inosine monophosphate dehydrogenase inhibitor, selectively inhibits the proliferation of T and B lymphocytes, thereby reducing antibody production and suppressing intraglomerular inflammation [9], and has been recommended by the KDIGO 2025 Clinical Practice Guideline as a corticosteroids-sparing agent for Chinese patients [8]. However, all these treatments can only alleviate the disease symptoms and cannot provide an etiological treatment. As a result, many IgAN patients remain at high risk of progression to ESRD, particularly those young adults from the Asian and Pacific regions [10–12]. Nefecon, a novel, intestinal-targeted release formulation of budesonide, specifically inhibits abnormal activation and excessive proliferation of intestinal mucosal cells, thereby reducing the production of galactose-deficient IgA1 (Gd-IgA1) at its source and subsequently decreasing the deposition of Gd-IgA1-containing immune complexes in the glomeruli [13]. Currently, Nefecon has been recommended by the KDIGO 2025 Clinical Practice Guideline for the etiological treatment of IgAN patients [8]. However, due to its high treatment cost, widespread clinical accessibility remains limited. Furthermore, during the treatment of Nefecon, patients still need to bear the potential risks of adverse reactions associated with corticosteroids [13, 14]. Therefore, exploring novel therapeutic strategies remains a current research focus in the field of IgAN. To date, the exact pathogenesis of IgAN has not been fully elucidated. The “multi-hit hypothesis” is the widely accepted framework for understanding the steps involved in the pathogenesis of IgAN [10]. According to this theoretical framework, the levels of Gd-IgA1 in blood circulation abnormally increase (Hit 1), which is the key initiation step of IgAN. Subsequently, these abnormally increased Gd-IgA1 molecules act as autoantigens, triggering the production of anti-glycan antibodies targeting Gd-IgA1 (Hit 2) and leading to the formation of circulating Gd-IgA1-containing immune complexes (Hit 3). Ultimately, these circulating immune complexes deposit in the mesangial region of the glomeruli (Hit 4), inducing the release of pro-inflammatory and pro-fibrotic mediators, which result in the proliferation of mesangial cell and the aggregation of inflammatory cell in the glomeruli [10, 15–18]. Subsequently, an uncontrolled inflammatory response is activated [19]. In addition, the activation of complement system further amplifies the inflammatory response in the mesangial region, leading to podocyte injury and glomerulosclerosis, as well as activation of proximal tubular epithelial cells and tubulointerstitial fibrosis [19–22]. The cytokines B-cell activating factor [BAFF, also known as BLyS (B lymphocyte stimulator)] and a proliferation-inducing ligand (APRIL), both the members of the tumor necrosis factor superfamily, play a key role in promoting class switch of B cells into IgA-producing plasmablasts and plasma cells [10, 23–25]. It has been confirmed that the dysregulation of BAFF and APRIL signaling pathway is associated with multiple core pathogenesis of IgAN, including elevated levels of serum Gd-IgA1, the formation of anti-Gd-IgA1 autoantibodies and Gd-IgA1-containing immune complexes, and the recruitment of inflammatory cells to the glomeruli [26–29]. Moreover, it has been found that the elevation levels of serum BAFF and APRIL are positively correlated with the severity of the disease in IgAN patients [30]. Therefore, targeted blockade of the BAFF and APRIL signaling pathway is expected to significantly improve the clinical outcome of IgAN patients. In recent years, it has been found that atacicept, a human recombinant fusion protein that targets binding to and inhibiting BAFF and APRIL, thereby blocking the proliferation of B lymphocytes and the maturation of T lymphocytes, can significantly lower the levels of circulating Gd-IgA1 and concomitantly reduce the levels of proteinuria in IgAN patients [31]. Telitacicept, a biosimilar of atacicept, has also been proven to effectively reduce the levels of proteinuria in IgAN patients [12]. However, until now, there have been no studies comprehensively evaluating the efficacy and safety of BAFF and APRIL dual antagonists in IgAN patients using meta-analysis method. Therefore, we intend to comprehensively evaluate the efficacy and safety of BAFF/APRIL dual antagonists in IgAN patients using meta-analysis method for the first time, aiming to provide evidence to support the clinical use of these drugs. Materials and methods This systematic review and meta-analysis was conducted in accordance with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline [32], and the trial protocol was registered in the International Prospective Register of Systematic Reviews (PROSEPRO) with the registration number CRD42025648717. Search strategy Literature search was performed using PubMed, Embase, Web of Science, Scopus and Cochrane Library from inception to 28 February 2025, employing the following search terms: [(“B cell activation factor and a proliferation-inducing ligand” OR “B lymphocyte stimulator and a proliferation-inducing ligand” OR “BAFF/APRIL” OR “BLyS/APRIL” OR “BAFF and APRIL” OR “BLyS and APRIL” AND (“antagonist” OR “inhibitor”)) OR “atacicept” OR “telitacicept” OR “povetacicept”] AND (“immunoglobulin A nephropathy” OR “IgA nephropathy” OR “IgAN”). Study selection Studies were eligible for inclusion if: (ⅰ) the study was published in English language; (ⅱ) the study was a randomized controlled trial (RCT); (ⅲ) the study included adult patients (≥ 18 years old) with biopsy-proven primary IgAN, urine protein excretion ≥ 0.75 g/d or protein-to-creatinine ratio (UPCR) ≥ 0.75 g/g, and estimated glomerular filtration rate (eGFR) ≥ 25 ml/min/1.73 m2; (ⅳ) the study compared BAFF/APRIL dual antagonist with other drugs or placebos; (ⅴ) the study lasted at least 24 weeks; (ⅵ) the study reported at least one required renal outcome or treatment-emergent adverse events (TEAEs). The following types of studies were excluded: duplicate studies, non-English studies, non-RCT studies, reviews, conference papers, case reports, case series reports, animal experiments, in vitro studies, studies involving patients with IgA vasculitis nephropathy or secondary IgAN (such as those associated with hepatic cirrhosis, hepatitis B or C infection, etc.), and studies where key data could not be effectively extracted. Outcome The primary outcomes included the change from baseline in 24-hour UPCR, eGFR and circulating Gd-IgA1. The second outcomes included the change from baseline in serum IgG, IgA and IgM. All drug-related TEAEs were also analyzed. Data extraction Two investigators (Y.Y. and M.H.) independently conducted the data extraction from eligible studies in accordance with the study protocol. For each study, the following data were extracted in detail: study characteristics (first-author name, publication year, clinical trial number and research type); population characteristics (sample size, gender, age, body weight, duration of disease, BP, 24-hour UPCR, 24-hour urine protein excretion, eGFR, Gd-IgA1, IgG, IgA and IgM); intervention strategy (drug name, dosage, route of administration, frequency of administration and duration of treatment); relevant outcomes after treatment and all drug-related TEAEs. Any disagreements in data extraction were solved by discussion with a third investigator (Z.F.). Quality assessment Two investigators (J.M. and Yun.Li) independently assessed the quality of eligible studies in accordance with the Cochrane Risk of Bias 2 tool [33]. Using this assessment tool, six domains were assessed in detail, including random sequence generation, allocation concealment, blinding of participants and researchers, binding of outcome assessment, incomplete outcome data, and selective reporting. Any discrepancies in quality assessment were solved by discussion with a third investigator (L.T.). Statistical analysis The statistical analysis was performed using RevMan software (version 5.4). Treatment outcomes, including changes from baseline in 24-hour UPCR, eGFR, circulating Gd-IgA1, serum IgG, IgA and IgM, were reported as mean difference (MD) with 95% confidence interval (CI). The proportion of patients experiencing drug-related TEAEs after treatment was presented as odds ratio (OR) with 95% CI. Given the potential heterogeneity among the included studies with respect to patients’ baseline characteristics, medication dosage, and follow-up duration, we conducted statistical analysis using the random-effects model, as recommended by the Cochrane Handbook. P < 0.05 was considered statistically significant. Results Literature search and study characteristics The study selection process is shown in Fig. 1. In total, 313 studies were identified in the initial literature search, of which 163 studies were excluded because of duplication. After screening the titles and/or abstracts, 127 studies were excluded as they did not meet the inclusion criteria. Subsequently, 23 studies were assessed by carefully reading the full text and 20 studies were further excluded (16 for conference abstracts, 1 for editorial comment, 2 for non-RCT studies and 1 for data that cannot be extracted). Finally, three studies (including 263 primary IgAN patients) were selected for our meta-analysis [12, 31, 34]. Among these three studies, Lv et al. [12]. , Barratt et al. [31]. and Lafayette et al. [34]. evaluated the efficacy and safety of BAFF/APRIL dual antagonists in IgAN patients at two, two and three dose groups, respectively. Given that our study aimed to comprehensively assess the efficacy and safety of BAFF/APRIL dual antagonists in IgAN patients, and the impact of different doses on treatment outcomes was not the focus of our study, each dose group of the three studies met our inclusion criteria. Therefore, for the convenience of statistical analysis, each dose group of the three studies was regarded as an independent study. PRISMA flow diagram of the study selection process In the three studies, the average disease duration of the patients ranged from 1.26 to 4.55 years. One study included patients with 24-hour proteinuria excretion ≥ 0.75 g/d and eGFR >35 ml/min per 1.73 m2 [12]. One study included patients with 24-hour UPCR ≥ 1 mg/mg or ≥ 0.75 mg/mg at screening but who had at least one documented ≥ 1 mg/mg within 12 months and eGFR ≥ 25 ml/min per 1.73 m2 [31]. One study included patients with 24-hour proteinuria excretion >0.75 g/d or UPCR >0.75 g/g and eGFR ≥ 35 ml/min per 1.73 m2 [34]. None of the three studies provided the Oxford classification results of the patients’ renal biopsies. Regarding drug intervention, two studies compared atacicept with placebo [31, 34], one study compared telitacicept with placebo [12]. The follow-up duration of the three studies spanned from 24 weeks to 72 weeks. All three studies reported the safety of BAFF/APRIL dual antagonists and treatment outcomes in whole or in part. The detailed characteristics of patients are presented in Table 1. Table 1Baseline characteristics of the included studies and participantsBarratt 2022a [1]Barratt 2022b [1]Lv 2023a [2]Lv 2023b [2]Lafayette 2024a [3]Lafayette 2024b [3]Lafayette 2024c [3]Study designA randomized, double-blind, placebo-controlled phase II studyA randomized, double-blind, placebo-controlled phase II studyA phase 2 randomized double-blind placebo-controlled trialA phase 2 randomized double-blind placebo-controlled trialA phase 2b, randomized, double-blind, placebo-controlled, clinical trialA phase 2b, randomized, double-blind, placebo-controlled, clinical trialA phase 2b, randomized, double-blind, placebo-controlled, clinical trialClinical trial numberNCT02808429NCT02808429NCT04291781NCT04291781NCT04716231NCT04716231NCT04716231Research institution17 centers in 3 countries17 centers in 3 countries21 centers in China21 centers in China65 centers in 13 countries65 centers in 13 countries65 centers in 13 countriesPopulation characteristicsAdults (aged ≥ 18 years) with biopsy-proven primary IgAN, an UPCR ≥ 1 mg/mg or ≥ 0.75 mg/mg at screening but who had at least one documented ≥ 1 mg/mg within 12 months and an eGFR ≥ 25 ml/min/1.73 m2Adults (aged ≥ 18 years) with biopsy-proven primary IgAN, an UPCR ≥ 1 mg/mg or ≥ 0.75 mg/mg at screening but who had at least one documented ≥ 1 mg/mg within 12 months and an eGFR ≥ 25 ml/min/1.73 m2Adults (aged ≥ 18 years) with biopsy-proven primary IgAN, proteinuria excretion ≥ 0.75 g/d and an eGFR > 35 ml/min/1.73 m2Adults (aged ≥ 18 years) with biopsy-proven primary IgAN, proteinuria excretion ≥ 0.75 g/d and an eGFR > 35 ml/min/1.73 m2Adults (aged ≥ 18 years) with biopsy-proven primary IgAN, proteinuria excretion > 0.75 g/d or UPCR > 0.75 g/g and an eGFR ≥ 35 ml/min/1.73 m2Adults (aged ≥ 18 years) with biopsy-proven primary IgAN, proteinuria excretion > 0.75 g/d or UPCR > 0.75 g/g and an eGFR ≥ 35 ml/min/1.73 m2Adults (aged ≥ 18 years) with biopsy-proven primary IgAN, proteinuria excretion > 0.75 g/d or UPCR > 0.75 g/g and an eGFR ≥ 35 ml/min/1.73 m2Intervention measureIntervention group: atacicept 25 mg once per week;control group: placeboIntervention group: atacicept 75 mg once per week;control group: placeboIntervention group: 160 mg once per week;Control group: placeboIntervention group: 240 mg once per week;Control group: placeboIntervention group: atacicept 25 mg once per week;Control group: placeboIntervention group: atacicept 75 mg once per week;Control group: placeboIntervention group: atacicept 150 mg once per week;Control group: placeboDuration of follow-up (weeks)72722424363636Sample size (n)Intervention group: 6; control group: 5Intervention group: 5; control group: 5Intervention group: 16;Control group: 14Intervention group: 14;Control group: 14Intervention group: 16;Control group: 34Intervention group: 33;Control group: 34Intervention group: 33;Control group: 34Sex, female (n)Intervention group: 5;Control group: 1Intervention group: 2; control group: 1Intervention group: 8;Control group: 4Intervention group: 9;Control group: 4Intervention group: 7;Control group: 15Intervention group: 14;Control group: 15Intervention group: 11;Control group: 15Age (years), mean ± SDIntervention group:41 ± 16.9;Control group: 46 ± 3.1Intervention group:43 ± 8.9;Control group: 46 ± 3.1Intervention group: 35.9 ± 9.88;Control group: 38.3 ± 6.91Intervention group: 36.8 ± 8.83;Control group: 38.3 ± 6.91Intervention group: 40 ± 15;Control group: 39 ± 13Intervention group: 41 ± 13;Control group: 39 ± 13Intervention group: 38 ± 11;Control group: 39 ± 13Race, nIntervention group: White 5, Asian 1, Other 0;Control group: White 4, Asian 1, Other 0Intervention group: White 2, Asian 1, Other 2;Control group: White 4, Asian 1, Other 0NANAIntervention group: White 7, Asian 7, Other 2;Control group: White 26, Asian 8, Other 0Intervention group: White 12, Asian 20, Other 1;Control group: White 26, Asian 8, Other 0Intervention group: White 17, Asian 16, Other 0;Control group: White 26, Asian 8, Other 0Course of the disease (years);Mean ± SD/ median (Q1, Q3)Intervention group: 2.17 (0.12, 2.99);Control group: 1.26 (1.05, 12.42)Intervention group: 2.56 (2.52, 4.62);Control group: 1.26 (1.05, 12.42)Intervention group: 4.55 (2.71, 7.72);Control group: 2.96 (2.39, 5.58)Intervention group: 4.43 (1.07, 6.04);Control group: 2.96 (2.39, 5.58)Intervention group: 1.7 ± 1.6;Control group: 2.1 ± 2.4Intervention group: 3.4 ± 2.8;Control group: 2.1 ± 2.4Intervention group: 3.3 ± 3.4;Control group: 2.1 ± 2.4BMI (kg/m2), mean ± SDNANAIntervention group: 25.98 ± 4.27;Control group: 26.29 ± 4.65Intervention group: 24.93 ± 4.00;Control group: 26.29 ± 4.65NANANASBP (mmHg), mean ± SDNANAIntervention group: 117.1 ± 12.83;Control group: 117.7 ± 11.78Intervention group: 117.1 ± 10.03;Control group: 117.7 ± 11.78Intervention group: 127 ± 8;Control group: 127 ± 13Intervention group: 127 ± 13;Control group: 127 ± 13Intervention group: 127 ± 12;Control group: 127 ± 13DBP (mmHg), mean ± SDNANAIntervention group: 78.7 ± 8.41;Control group: 77.3 ± 10.19Intervention group: 77.1 ± 7.67;Control group: 77.3 ± 10.19Intervention group: 81 ± 8;Control group: 77 ± 8Intervention group: 80 ± 9;Control group: 77 ± 8Intervention group: 80 ± 9;Control group: 77 ± 824-hour Urinary protein excretion (g/d), mean ± SD /median (Q1, Q3)Intervention group: 2.1 (1.9, 2.9);Control group: 3.2 (2.3, 3.3)Intervention group: 1.7 (1.6, 2.3);Control group: 3.2 (2.3, 3.3)Intervention group: 1.63 (1.29, 2.41);Control group: 1.86 (1.57, 2.36)Intervention group: 1.34 (1.14, 2.01);Control group: 1.86 (1.57, 2.36)Intervention group: 2.3 ± 1.0;Control group: 2.0 ± 0.9Intervention group: 2.1 ± 1.0;Control group: 2.0 ± 0.9Intervention group: 2.3 ± 1.2;Control group: 2.0 ± 0.924-hour UPCR (g/g), median (Q1, Q3)Intervention group: 1.8 (0.8, 2.2);Control group: 1.6 (1.5, 1.6)Intervention group: 1.4 (1.3, 1.7);Control group: 1.6 (1.5, 1.6)NANAIntervention group: 1.4 (1.1, 1.9);Control group: 1.5 (0.9, 2.1)Intervention group: 1.4 (1.2, 1.9);Control group: 1.5 (0.9, 2.1)Intervention group: 1.4 (1.0, 2.2);Control group: 1.5 (0.9, 2.1)eGFR (ml/min/1.73m2), median (Q1, Q3)Intervention group: 57 (53, 85)Control group: 49 (48, 54)Intervention group: 55(52, 92)Control group: 49 (48, 54)Intervention group: 71.67 (58.83, 93.42);Control group: 91.20 (67.73, 108.83)Intervention group: 70.17 (57.43, 94.94);Control group: 91.20 (67.73, 108.83)Intervention group: 65 (51, 90);Control group: 57 (42, 87)Intervention group: 63 (43, 79);Control group: 57 (42, 87)Intervention group: 49 (41, 63);Control group: 57 (42, 87)IgA (g/l), mean ± SD/ median (Q1, Q3)Intervention group: 3.58 ± 1.22;Control group: 3.97 ± 1.72Intervention group: 3.02 ± 0.85;Control group: 3.97 ± 1.72Intervention group: 2.94 (2.80, 3.62);Control group: 3.02 (2.26, 3.83)Intervention group: 3.61 (2.01, 4.14);Control group: 3.02 (2.26, 3.83)Intervention group: 3.15 ± 1.43;Control group: 3.37 ± 1.54Intervention group: 3.13 ± 1.31;Control group: 3.37 ± 1.54Intervention group: 3.20 ± 1.00;Control group: 3.37 ± 1.54IgG (g/l), mean ± SD/ median (Q1, Q3)Intervention group: 9.45 ± 1.82;Control group: 10.51 ± 2.63Intervention group: 10.89 ± 1.10;Control group: 10.51 ± 2.63Intervention group: 11.14 (10.04, 12.60);Control group: 9.33 (8.30, 11.14)Intervention group: 10.05 (8.65, 12.51);Control group: 9.33 (8.30, 11.14)Intervention group: 10.18 ± 2.17;Control group: 11.53 ± 3.05Intervention group: 11.59 ± 2.89;Control group: 11.53 ± 3.05Intervention group: 10.59 ± 2.06;Control group: 11.53 ± 3.05IgM(g/l), mean ± SD/ median (Q1, Q3)Intervention group: 0.90 ± 0.55;Control group: 1.29 ± 0.51Intervention group: 1.09 ± 0.30;Control group: 1.29 ± 0.51Intervention group: 1.06 (0.80, 1.35);Control group: 0.91 (0.63, 1.07)Intervention group: 0.77 (0.67, 0.94);Control group: 0.91 (0.63, 1.07)Intervention group: 0.98 ± 0.44;Control group: 1.02 ± 0.50Intervention group: 1.21 ± 1.00;Control group: 1.02 ± 0.50Intervention group: 0.94 ± 0.56;Control group: 1.02 ± 0.50Gd-IgA1 (ng/ml), mean ± SD/ median (Q1, Q3)Intervention group: 6258 ± 3211;Control group: 7690 ± 3642Intervention group: 6052 ± 2773;Control group: 7690 ± 3642NANAIntervention group: 6292 ± 4572;Control group: 6340 ± 3697Intervention group: 5813 ± 3573;Control group: 6340 ± 3697Intervention group: 5646 ± 2697;Control group: 6340 ± 3697History of tonsillectomy therapy, nIntervention group: 0;Control group: 0Intervention group: 2;Control group: 0NANANANANAHistory of systemic corticosteroids therapy, nIntervention group: 2;Control group: 1Intervention group: 1;Control group: 1Intervention group: 4;Control group: 2Intervention group: 0;Control group: 2NANANAHistory of other immunosuppressant therapy, nNANAIntervention group: 4;Control group 2Intervention group: 5;Control group 2NANANAUse of RAASi, nIntervention group: ACEi only 3, ARB only 3, ACEi and ARB 0Control group: ACEi only 3, ARB only 2, ACEi and ARB 0Intervention group: ACEi only 1, ARB only 4, ACEi and ARB 0;Control group: ACEi only 3, ARB only 2, ACEi and ARB 0NANAIntervention group: ACEi only 10, ARB only 4, ACEi and ARB 1;Control group: ACEi only 11, ARB only 19, ACEi and ARB 2Intervention group: ACEi only 6, ARB only 21, ACEi and ARB 3;Control group: ACEi only 11, ARB only 19, ACEi and ARB 2Intervention group: ACEi only 6, ARB only 23, ACEi and ARB 3;Control group: ACEi only 11, ARB only 19, ACEi and ARB 2Use of SGLT2i, nNANANANAIntervention group: 3;Control group: 6Intervention group: 3;Control group: 6Intervention group: 4;Control group: 6BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; UPCR, urine protein-creatinine ratio; RAASi, renin-angiotensin-aldosterone system inhibitor; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; SGLT2i, sodium-glucose cotransporter-2 inhibitor; NA, not available References 1. Barratt J, Tumlin J, Suzuki Y, et al. Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria. Kidney Int Rep. 2022;7(8):1831–18412. Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep. 2023;8(3):499–5063. Lafayette R, Barbour S, Israni R, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024;105(6):1306–1315 Baseline characteristics of the included studies and participants Intervention group: atacicept 25 mg once per week; control group: placebo Intervention group: atacicept 75 mg once per week; control group: placebo Intervention group: 160 mg once per week; Control group: placebo Intervention group: 240 mg once per week; Control group: placebo Intervention group: atacicept 25 mg once per week; Control group: placebo Intervention group: atacicept 75 mg once per week; Control group: placebo Intervention group: atacicept 150 mg once per week; Control group: placebo Intervention group: 16; Control group: 14 Intervention group: 14; Control group: 14 Intervention group: 16; Control group: 34 Intervention group: 33; Control group: 34 Intervention group: 33; Control group: 34 Intervention group: 5; Control group: 1 Intervention group: 8; Control group: 4 Intervention group: 9; Control group: 4 Intervention group: 7; Control group: 15 Intervention group: 14; Control group: 15 Intervention group: 11; Control group: 15 Intervention group:41 ± 16.9; Control group: 46 ± 3.1 Intervention group:43 ± 8.9; Control group: 46 ± 3.1 Intervention group: 35.9 ± 9.88; Control group: 38.3 ± 6.91 Intervention group: 36.8 ± 8.83; Control group: 38.3 ± 6.91 Intervention group: 40 ± 15; Control group: 39 ± 13 Intervention group: 41 ± 13; Control group: 39 ± 13 Intervention group: 38 ± 11; Control group: 39 ± 13 Intervention group: White 5, Asian 1, Other 0; Control group: White 4, Asian 1, Other 0 Intervention group: White 2, Asian 1, Other 2; Control group: White 4, Asian 1, Other 0 Intervention group: White 7, Asian 7, Other 2; Control group: White 26, Asian 8, Other 0 Intervention group: White 12, Asian 20, Other 1; Control group: White 26, Asian 8, Other 0 Intervention group: White 17, Asian 16, Other 0; Control group: White 26, Asian 8, Other 0 Course of the disease (years); Mean ± SD/ median (Q1, Q3) Intervention group: 2.17 (0.12, 2.99); Control group: 1.26 (1.05, 12.42) Intervention group: 2.56 (2.52, 4.62); Control group: 1.26 (1.05, 12.42) Intervention group: 4.55 (2.71, 7.72); Control group: 2.96 (2.39, 5.58) Intervention group: 4.43 (1.07, 6.04); Control group: 2.96 (2.39, 5.58) Intervention group: 1.7 ± 1.6; Control group: 2.1 ± 2.4 Intervention group: 3.4 ± 2.8; Control group: 2.1 ± 2.4 Intervention group: 3.3 ± 3.4; Control group: 2.1 ± 2.4 Intervention group: 25.98 ± 4.27; Control group: 26.29 ± 4.65 Intervention group: 24.93 ± 4.00; Control group: 26.29 ± 4.65 Intervention group: 117.1 ± 12.83; Control group: 117.7 ± 11.78 Intervention group: 117.1 ± 10.03; Control group: 117.7 ± 11.78 Intervention group: 127 ± 8; Control group: 127 ± 13 Intervention group: 127 ± 13; Control group: 127 ± 13 Intervention group: 127 ± 12; Control group: 127 ± 13 Intervention group: 78.7 ± 8.41; Control group: 77.3 ± 10.19 Intervention group: 77.1 ± 7.67; Control group: 77.3 ± 10.19 Intervention group: 81 ± 8; Control group: 77 ± 8 Intervention group: 80 ± 9; Control group: 77 ± 8 Intervention group: 80 ± 9; Control group: 77 ± 8 Intervention group: 2.1 (1.9, 2.9); Control group: 3.2 (2.3, 3.3) Intervention group: 1.7 (1.6, 2.3); Control group: 3.2 (2.3, 3.3) Intervention group: 1.63 (1.29, 2.41); Control group: 1.86 (1.57, 2.36) Intervention group: 1.34 (1.14, 2.01); Control group: 1.86 (1.57, 2.36) Intervention group: 2.3 ± 1.0; Control group: 2.0 ± 0.9 Intervention group: 2.1 ± 1.0; Control group: 2.0 ± 0.9 Intervention group: 2.3 ± 1.2; Control group: 2.0 ± 0.9 Intervention group: 1.8 (0.8, 2.2); Control group: 1.6 (1.5, 1.6) Intervention group: 1.4 (1.3, 1.7); Control group: 1.6 (1.5, 1.6) Intervention group: 1.4 (1.1, 1.9); Control group: 1.5 (0.9, 2.1) Intervention group: 1.4 (1.2, 1.9); Control group: 1.5 (0.9, 2.1) Intervention group: 1.4 (1.0, 2.2); Control group: 1.5 (0.9, 2.1) Intervention group: 57 (53, 85) Control group: 49 (48, 54) Intervention group: 55(52, 92) Control group: 49 (48, 54) Intervention group: 71.67 (58.83, 93.42); Control group: 91.20 (67.73, 108.83) Intervention group: 70.17 (57.43, 94.94); Control group: 91.20 (67.73, 108.83) Intervention group: 65 (51, 90); Control group: 57 (42, 87) Intervention group: 63 (43, 79); Control group: 57 (42, 87) Intervention group: 49 (41, 63); Control group: 57 (42, 87) Intervention group: 3.58 ± 1.22; Control group: 3.97 ± 1.72 Intervention group: 3.02 ± 0.85; Control group: 3.97 ± 1.72 Intervention group: 2.94 (2.80, 3.62); Control group: 3.02 (2.26, 3.83) Intervention group: 3.61 (2.01, 4.14); Control group: 3.02 (2.26, 3.83) Intervention group: 3.15 ± 1.43; Control group: 3.37 ± 1.54 Intervention group: 3.13 ± 1.31; Control group: 3.37 ± 1.54 Intervention group: 3.20 ± 1.00; Control group: 3.37 ± 1.54 Intervention group: 9.45 ± 1.82; Control group: 10.51 ± 2.63 Intervention group: 10.89 ± 1.10; Control group: 10.51 ± 2.63 Intervention group: 11.14 (10.04, 12.60); Control group: 9.33 (8.30, 11.14) Intervention group: 10.05 (8.65, 12.51); Control group: 9.33 (8.30, 11.14) Intervention group: 10.18 ± 2.17; Control group: 11.53 ± 3.05 Intervention group: 11.59 ± 2.89; Control group: 11.53 ± 3.05 Intervention group: 10.59 ± 2.06; Control group: 11.53 ± 3.05 Intervention group: 0.90 ± 0.55; Control group: 1.29 ± 0.51 Intervention group: 1.09 ± 0.30; Control group: 1.29 ± 0.51 Intervention group: 1.06 (0.80, 1.35); Control group: 0.91 (0.63, 1.07) Intervention group: 0.77 (0.67, 0.94); Control group: 0.91 (0.63, 1.07) Intervention group: 0.98 ± 0.44; Control group: 1.02 ± 0.50 Intervention group: 1.21 ± 1.00; Control group: 1.02 ± 0.50 Intervention group: 0.94 ± 0.56; Control group: 1.02 ± 0.50 Intervention group: 6258 ± 3211; Control group: 7690 ± 3642 Intervention group: 6052 ± 2773; Control group: 7690 ± 3642 Intervention group: 6292 ± 4572; Control group: 6340 ± 3697 Intervention group: 5813 ± 3573; Control group: 6340 ± 3697 Intervention group: 5646 ± 2697; Control group: 6340 ± 3697 Intervention group: 0; Control group: 0 Intervention group: 2; Control group: 0 Intervention group: 2; Control group: 1 Intervention group: 1; Control group: 1 Intervention group: 4; Control group: 2 Intervention group: 0; Control group: 2 Intervention group: 4; Control group 2 Intervention group: 5; Control group 2 Intervention group: ACEi only 3, ARB only 3, ACEi and ARB 0 Control group: ACEi only 3, ARB only 2, ACEi and ARB 0 Intervention group: ACEi only 1, ARB only 4, ACEi and ARB 0; Control group: ACEi only 3, ARB only 2, ACEi and ARB 0 Intervention group: ACEi only 10, ARB only 4, ACEi and ARB 1; Control group: ACEi only 11, ARB only 19, ACEi and ARB 2 Intervention group: ACEi only 6, ARB only 21, ACEi and ARB 3; Control group: ACEi only 11, ARB only 19, ACEi and ARB 2 Intervention group: ACEi only 6, ARB only 23, ACEi and ARB 3; Control group: ACEi only 11, ARB only 19, ACEi and ARB 2 Intervention group: 3; Control group: 6 Intervention group: 3; Control group: 6 Intervention group: 4; Control group: 6 BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; UPCR, urine protein-creatinine ratio; RAASi, renin-angiotensin-aldosterone system inhibitor; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; SGLT2i, sodium-glucose cotransporter-2 inhibitor; NA, not available References 1. Barratt J, Tumlin J, Suzuki Y, et al. Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria. Kidney Int Rep. 2022;7(8):1831–1841 2. Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep. 2023;8(3):499–506 3. Lafayette R, Barbour S, Israni R, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024;105(6):1306–1315 Quality assessment As shown in Figs. 2 and 3, the three included studies were all double-blind RCTs and the random sequences were generated by computer software. Except for the data monitoring committee, neither the patients nor the practitioners were aware of the trial-group assignments. Therefore, there was no significant selection bias, performance bias or detection bias in any of the three included studies. Among the three studies, although individual patients dropped in each study, the reasons and numbers for dropout were clearly documented. Given that two of the studies had relatively large sample sizes [12, 34], the dropout of individual patients did not have a substantial impact on the result analysis. Therefore, there was no significant attrition bias in these two studies [12, 34]. However, the sample size of the third study was small [31], patient dropout could potentially affect the result analysis. Thus, attrition bias may be present in this study. Furthermore, no evidence indicates that there is selective reporting in any of the three included studies. Therefore, overall, the quality of the three included studies is relatively high, which can effectively ensure the reliability of the results. Risk of bias in each included study Summary of risk of bias for all included studies Effects of treatment on proteinuria The percentage reduction of 24-hour UPCR from baseline was presented in Fig. 4. Compared with the control group, BAFF/APRIL dual antagonists group achieved a greater percentage reduction from baseline in 24-hour UPCR (MD -36.67, 95% CI -40.31 to -33.03, P < 0.00001). Similarly, as presented in Supplementary data, Figure S1, the levels of 24-hour urine protein excretion in the BAFF/APRIL dual antagonist group were lower than that in the control group, even though there was no statistical difference (MD -0.71, 95% CI -1.51 to -0.08, P = 0.08). Comparison of the percentage change from baseline in 24-hour UPCR between the BAFF/APRIL dual antagonist group and the control group Effects of treatment on eGFR Compared with the control group, BAFF/APRIL dual antagonist group had a greater increase from baseline in eGFR (MD 9.65, 95% CI 7.73 to 11.57, P < 0.00001, Fig. 5). Consistent with this, the annualized eGFR slope estimate from baseline in the BAFF/APRIL dual antagonist group was significantly higher than that in the control group (MD 5.77, 95% CI 4.62 to 6.91, P < 0.00001, Supplementary data, Figure S2). Comparison of the change from baseline in eGFR between the BAFF/APRIL dual antagonist group and the control group Effects of treatment on circulating Gd-IgA1 As shown in Fig. 6, the percentage reduction of circulating Gd-IgA1 from baseline in the BAFF/APRIL dual antagonist group was significantly higher than that in the control group (MD -45.55, 95% CI -61.33 to -29.78, P < 0.00001). Comparison of the percentage change from baseline in circulating Gd-IgA1 between the BAFF/APRIL dual antagonist group and the control group Safety Influences of treatment on serum IgG, IgA and IgM The influences of BAFF/APRIL dual antagonists on serum IgG, IgA and IgM were presented in Fig. 7. Compared with the control group, BAFF/APRIL dual antagonist group achieved a greater percentage reduction from baseline in serum IgG (MD -22.65, 95% CI -33.83 to -11.48, P < 0.00001, Fig. 7A), IgA (MD -41.41, 95% CI -55.35 to -27.48, P < 0.00001, Fig. 7B) and IgM (MD -63.39, 95% CI -77.29 to -49.50, P < 0.00001, Fig. 7C). (A) Comparison of the percentage change from baseline in serum IgG between the BAFF/APRIL dual antagonist group and the control group; (B) Comparison of the percentage change from baseline in serum IgA between the BAFF/APRIL dual antagonist group and the control group; (C) Comparison of the percentage change from baseline in serum IgM between the BAFF/APRIL dual antagonist group and the control group Drug-related TEAEs As shown in Table 2, the overall incidence of drug-related TEAEs in the BAFF/APRIL dual antagonist group was similar to that in the control group (OR 1.74, 95% CI 1.01 to 3.00, P = 0.05), and no case of death was reported in the BAFF/APRIL dual antagonist group. In addition, no significant difference in the incidence of infection-related TEAEs was observed between the BAFF/APRIL dual antagonist group and the control group (OR 1.39, 95% CI 0.83 to 2.32, P = 0.21). The common infection-related TEAEs in the BAFF/APRIL dual antagonist group included COVID-19, other viral infections, upper respiratory tract infection, nasopharyngitis, urinary tract infection and tonsillitis. Fortunately, the incidences of all these events showed no significant difference from those in the control group. Moreover, among the BAFF/APRIL dual antagonist group, other frequently observed drug-related TEAEs included hypersensitivity and hyperuricemia. Similarly, the incidences of these two events also showed no significant difference compared with those in the control group. Table 2Comparison of the drug-related TEAEs between the BAFF/APRIL dual antagonist group and the control groupTEAEsStudiesBAFF/APRIL dual antagonist group (n/N)Control group (n/N)OR (95% CI)P valueHeterogeneityTotal of drug-related TEAEs778/12368/1401.74 (1.01, 3.00)0.05Tau2 = 0.00, Chi2 = 4.70, df = 6 (P = 0.58), I2 = 0%Infection-related TEAEs752/12347/1401.39 (0.83, 2.32)0.21Tau2 = 0.00, Chi2 = 4.82, df = 6 (P = 0.57), I2 = 0%COVID-19321/8218/1021.60 (0.78, 3.29)0.20Tau2 = 0.00, Chi2 = 0.04, df = 2 (P = 0.98), I2 = 0%Other virus infection54/9311/1120.50 (0.16, 1.49)0.21Tau2 = 0.00, Chi2 = 1.33, df = 4 (P = 0.86), I2 = 0%Upper respiratory infection416/9612/961.25 (0.44, 3.57)0.67Tau2 = 0.15, Chi2 = 3.42, df = 3 (P = 0.33), I2 = 12%Nasopharyngitis34/823/1021.59 (0.33, 7.64)0.56Tau2 = 0.00, Chi2 = 0.74, df = 2 (P = 0.69), I2 = 0%Urinary tract infection34/820/1025.07 (0.80, 31.95)0.08Tau2 = 0.00, Chi2 = 0.45, df = 2 (P = 0.80), I2 = 0%Tonsillitis22/490/684.60 (0.46, 45.68)0.19Tau2 = 0.00, Chi2 = 0.00, df = 1 (P = 0.75), I2 = 0%Injection site reactions426/410/3830.94 (6.43, 148.75)< 0.0001Tau2 = 0.00, Chi2 = 0.52, df = 3 (P = 0.92), I2 = 0%Blood IgG decreased29/302/285.55 (1.08, 28.56)0.04Tau2 = 0.00, Chi2 = 0.01, df = 1 (P = 0.94), I2 = 0%Blood IgM decreased210/300/2815.25 (1.83, 127.48)0.01Tau2 = 0.00, Chi2 = 0.01, df = 1 (P = 0.93), I2 = 0%Hypersensitivity reactions56/938/1120.83 (0.23, 2.97)0.77Tau2 = 0.00, Chi2 = 3.83, df = 4 (P = 0.43), I2 = 0%Hyperuricemia24/304/280.92 (0.20, 4.30)0.91Tau2 = 0.00, Chi2 = 0.46, df = 1 (P = 0.50), I2 = 0%Other41/883/1070.66 (0.13, 3.42)0.62Tau2 = 0.00, Chi2 = 1.10, df = 3 (P = 0.78), I2 = 0%TEAEs, treatment-emergent adverse events; n, the number of patients who experienced TEAEs; N, the total number of patients included Comparison of the drug-related TEAEs between the BAFF/APRIL dual antagonist group and the control group TEAEs, treatment-emergent adverse events; n, the number of patients who experienced TEAEs; N, the total number of patients included However, the incidence of injection site reactions in the BAFF/APRIL dual antagonist group was significantly higher than that in the control group (OR 30.94, 95% CI 6.43 to 148.75, P < 0.0001), and the common injection site reactions included erythema, pruritus and bruising. Furthermore, the incidence of decreased serum IgG and IgM in the BAFF/APRIL dual antagonist group were all significantly higher than those in the control group (OR 5.55, 95% CI 1.08 to 28.56, P = 0.04; OR 15.25, 95% CI 1.82 to 127.48, P = 0.01, respectively). Discussion In this meta-analysis, the efficacy and safety of BAFF/APRIL dual antagonists in IgAN patients were systematically evaluated for the first time. Based on the current results of three Phase II clinical trials, we found that, compared with the control treatment, BAFF/APRIL dual antagonists may reduce the levels of 24-hour UPCR and circulating Gd-IgA1, while concomitantly delaying the decline of eGFR. Notably, although our meta-analysis did not show a significant increase in the risk of infectious disease among patients treated with BAFF/APRIL dual antagonists, these agents were associated with significant reductions in serum IgG, IgA, and IgM. Therefore, the potential risk of excessive immunosuppression still needs to be given close attention. Moreover, due to the limited number of studies and participants included in our research, our findings may not fully reflect the therapeutic effects of BAFF/APRIL dual antagonists in IgAN patients. It is highly necessary to conduct more high-quality and large-sample RCTs to further explore the long-term efficacy and safety of BAFF/APRIL dual antagonists in IgAN patients. Proteinuria, the most widely recognized and well-studied risk factor for progression to ESRD in IgAN patients, has been validated as a surrogate endpoint for evaluating the treatment efficacy in this population [35, 36]. Therefore, in our meta-analysis, the effect of BAFF/APRIL dual antagonists on 24-hour UPCR was evaluated in detail. Compared with the control group, BAFF/APRIL dual antagonist group achieved a significant 36.67% reduction from baseline in 24-hour UPCR among IgAN patients in our meta-analysis. This result is consistent with those of other studies. In a real-world observational case-control study, Dong et al. found that telitacicept could reduce the median proteinuria in IgAN patients by 54.6% from baseline after 3 months of treatment [37]. Likewise, in a multicenter retrospective cohort study, Liu et al. also found that telitacicept could lower proteinuria by 46.3% from baseline after 4 months of treatment [38]. Additionally, in an open-label study, Madan et al. found that povetacicept resulted in a 64% reduction in UPCR from baseline after 9 months of treatment in IgAN patients [39]. Furthermore, compared with control treatment, BAFF/APRIL dual antagonists could reduce proteinuria by an average of 0.71 g per day in IgAN patients in our meta-analysis, even though there was no statistical difference. All these findings suggest that BAFF/APRIL dual antagonists may decrease the level of proteinuria in IgAN patients. Similar to proteinuria, eGFR, another independent risk factor for progression to ESRD in IgAN patients, is also been recognized as an alternative endpoint for evaluating the treatment efficacy in this population [6, 40]. Therefore, the effect of BAFF/APRIL dual antagonists on eGFR in IgAN patients was also carefully evaluated. As expected, the eGFR level in the BAFF/APRIL dual antagonist group was significantly higher than that in the control group in our meta-analysis. This result is supported by the findings of Wang et al. [41]. In their retrospective case-control study, Wang et al. found that, after 24 weeks of treatment with telitacicept, the eGFR levels of IgAN patients exhibited a significant increase relative to the baseline, regardless of whether the patients had previously been treated with corticosteroid and/or immunosuppressant [41]. Similarly, in a real-world observational case-control study, Dong et al. found that, compared with supportive and immunosuppressive therapies, telitacicept could significantly attenuate the decline of eGFR in IgAN patients [37]. Moreover, compared with the control group, treatment with BAFF/APRIL dual antagonists could significantly increase the annualized eGFR slope estimate from baseline in our meta-analysis. All these findings indicate that BAFF/APRIL dual antagonist may attenuate the decline of eGFR in IgAN patients. As the initiating factor of IgAN, persistently high levels of circulating Gd-IgA1 are closely associated with the poor prognosis of IgAN patients [18]. Reducing the level of circulating Gd-IgA1 is expected to significantly slow down the progression of IgAN patients. Therefore, the change of circulating Gd-IgA1 from baseline in IgAN patients was carefully evaluated in our meta-analysis. Compared with the control treatment, BAFF/APRIL dual antagonists resulted in a 45.55% reduction from baseline in the level of circulating Gd-IgA1 in our meta-analysis. This result is consistent with the findings of Zan et al. [42]. who found that telitacicept could result in a 43.9% reduction from baseline in circulating Gd-IgA1 after 24 weeks of treatment. In an open-label study, Manda et al. [39]. observed that povetacicept achieved a 69% reduction relative to baseline in circulating Gd-IgA1 after 9 months of treatment in IgAN patients [39]. Furthermore, in a long-term follow-up study lasting 96 weeks, Barratt et al. observed that atacicept could still significantly reduce the levels of circulating Gd-IgA1 in IgAN patients [43]. All these results demonstrate that BAFF/APRIL dual antagonists may reduce the level of circulating Gd-IgA1 in IgAN patients. In addition to the therapeutic efficacy, the safety of BAFF/APRIL dual antagonists in IgAN patients was also carefully assessed in our meta-analysis. As previously mentioned, the overall incidence of drug-related TEAEs in the BAFF/APRIL dual antagonist group was similar to that in the control group, and no case of death was observed in the BAFF/APRIL dual antagonist group. All these findings are consistent with those of other studies [37, 38, 41], indicating that the safety of BAFF/APRIL dual antagonists may be acceptable. Considering that BAFF/APRIL dual antagonists can block the proliferation of B lymphocytes and maturation of T lymphocytes, they may potentially affect the immune status of IgAN patients and thus increase the risk of infection with pathogenic microorganisms, such as bacteria and viruses. In particular, we found that BAFF/APRIL dual antagonist group could significantly lower the levels of serum IgG, IgA and IgM in IgAN patients compared to the control group in our meta-analysis. Additionally, among the drug-related TEAEs, the incidences of decreased serum IgG and IgM in the BAFF/APRIL dual antagonist group were also significantly higher than those in the control group. These results are supported by the findings of Wallace et al. in other indications [44], who found that atacicept could significantly reduce the levels of serum IgG, IgA and IgM in patients with systemic lupus erythematosus. Similarly, Huang et al. also discovered that telitacicept could significantly reduce the levels of serum IgG, IgA and IgM in patients with lupus nephritis in a real-world retrospective study [45]. All these findings indicate that BAFF/APRIL dual antagonists may indeed decrease the levels of serum IgG, IgA and IgM in IgAN patients, potentially weakening the immune capacity of these patients. Fortunately, the risk of patients being infected by pathogenic microorganisms did not increase in our meta-analysis. In agreement with this finding, Wang et al. [41]. and Dong et al. [37]. also found similar results in their studies. However, considering that BAFF/APRIL dual antagonists could reduce the levels of IgG, IgA and IgM in IgAN patients by 22.65%, 41.41% and 63.39% respectively, such marked reductions may significantly compromise patients’ immune function. According to the U.S. guidelines for the diagnosis and management of primary immunodeficiency, a reduction in IgG levels exceeding 50% in adults, especially when accompanied by a decline in IgA levels, significantly increases the risk of infections [46]. In our study, although the decline in IgG levels in IgAN patients receiving BAFF/APRIL dual antagonists therapy had not yet reached the 50% threshold, it was accompanied by significant decrease in both IgA and IgM levels. Therefore, based on these findings, we cautiously speculate that the risk of immunosuppression associated with BAFF/APRIL dual antagonists in IgAN patients might be manageable, but the long-term safety profile still warrants attention. Clinically, it is strongly recommended to regularly monitor the levels of immunoglobulins (especially IgG levels) during the use of these agents. Moreover, as previously reported in studies [37, 41, 45, 47], BAFF/APRIL dual antagonists may cause injection site reactions. We obtained a similar result in our meta-analysis, indicating that injection site reactions may indeed be a common adverse reaction of BAFF/APRIL dual antagonists. It should be particularly noted that although BAFF/APRIL dual antagonists may improve the prognosis of IgAN patients and demonstrate an acceptable safety profile, as with other conventional immunosuppressive agents, their clinical use requires a comprehensive assessment of patients’ clinical and pathological characteristics, especially in those with a disease duration exceeding 5 or even 10 years. Such patients often exhibit advanced renal interstitial fibrosis and glomerulosclerosis [48], which may significantly diminish their response to immunosuppressive therapy. Therefore, when necessary, a repeat renal biopsy should be considered to dynamically monitor histopathological changes, thereby facilitating the rational application of BAFF/APRIL dual antagonists in IgAN patients. Limitations Although the studies included in our meta-analysis are all double-blind RCTs with relatively high-quality, which undoubtedly provide strong support for the reliability of the research results, several limitations must be acknowledged. First, due to the limited number of included studies, small sample size and relatively short study duration, our findings might not be able to fully and accurately reflect the efficacy and safety of BAFF/APRIL dual antagonists in IgAN patients. Second, the studies included in our study are all phase Ⅱ clinical trials, and no phase Ⅲ clinical trials were included. Therefore, the data collection may be insufficient, which may have a potentially impact on the analysis of the final results. Third, during the process of pooled analysis, as the control group data were repeatedly included, it may lead to an imbalance in statistical weights, introduce selection bias, and thereby weaken the robustness and extrapolation of the results. Fourth, the differences in drug type, dosage, and treatment duration among these included studies may also have a certain impact on the research results. Given these limitations, the findings of our study should be interpreted with caution. Nevertheless, our findings can still provide a valuable theoretical foundation for further research with larger sample sizes. Conclusions Based on the currently limited evidence, we cautiously conclude that BAFF/APRIL dual antagonists may reduce the levels of 24-hour UPCR and circulating Gd-IgA1 in patients with IgAN, while concomitantly delay the decline of eGFR. However, it should be noted that BAFF/APRIL dual antagonists may cause injection site reactions. More importantly, BAFF/APRIL dual antagonists may reduce the levels of serum IgG, IgA and IgM, thereby weakening the immune function of patients. It is highly necessary to conduct more high-quality and large-sample RCTs to further explore the long-term efficacy and safety of BAFF/APRIL dual antagonists in IgAN patients. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Not applicable. Author contributions Z.T., Yux.Li and Yan.Li were responsible for the concept, design, statistical analysis, and manuscript writing. Y.Y., M.H. and Z.F. were responsible for the literature search and data collection. J.M., Yun.Li and L.T. were responsible for the literature quality assessment. Z.F. and L.T. were responsible for critical revision of the manuscript. All authors have read and approved the final manuscript. Funding This study was supported by the National Natural Science Foundation of China (Grant No. 82505166), Cultivation Discipline of Chongqing Hospital of Traditional Chinese Medicine (Clinical Pharmacy), Chongqing Key Specialty of Clinical Pharmacy, and National Advantageous Specialty of Traditional Chinese Medicine (Clinical Pharmacy). Data availability Data is provided within the manuscript or supplementary information files. Declarations Ethical approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Yanyan Li, Email: 403819282@qq.com. Yuxia Li, Email: 1790355893@qq.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement Data is provided within the manuscript or supplementary information files.